Join Growin Stock Community!

麗彤6539.TW Overview

TW StockBiotech. & Medical
(No presentation for 6539)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

麗彤（6539）Overall Performance

麗彤（6539）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

麗彤（6539） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

麗彤（6539）Key Information

麗彤（6539）Profile

DV Biomed Co., Ltd. manufactures and sells medical-grade skin care products in Taiwan and internationally. The company provides health and slimming services; and acts as an agent of medical beauty fillers and medical beauty equipment. It also offers health food, including light and energy drinks; face care; and beauty products and services. The company was founded in 2011 and is based in Taipei, Taiwan.

麗彤（6539）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
8.84
PE Ratio (TTM)
6.64
Forward PE
-
PS Ratio (TTM)
0.63
PB Ratio
2.98
Price-to-FCF
2.64
METRIC
VALUE
vs. INDUSTRY
Gross Margin
56.69%
Net Margin
9.56%
Revenue Growth (YoY)
-39.14%
Profit Growth (YoY)
-38.19%
3-Year Revenue Growth
-27.54%
3-Year Profit Growth
-19.45%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
8.84
PE Ratio (TTM)
6.64
Forward PE
-
PS Ratio (TTM)
0.63
PB Ratio
2.98
Price-to-FCF
2.64
Gross Margin
56.69%
Net Margin
9.56%
Revenue Growth (YoY)
-39.14%
Profit Growth (YoY)
-38.19%
3-Year Revenue Growth
-27.54%
3-Year Profit Growth
-19.45%
default symbol

6539

麗彤

58.70D

0.68%

(0.01)

  • When is 6539's latest earnings report released?

    The most recent financial report for 麗彤 (6539) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6539's short-term business performance and financial health. For the latest updates on 6539's earnings releases, visit this page regularly.

  • Where does 6539 fall in the P/E River chart?

    According to historical valuation range analysis, 麗彤 (6539)'s current price-to-earnings (P/E) ratio is 20.88, placing it in the Watch zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • How much cash does 6539 have?

    At the end of the period, 麗彤 (6539) held Total Cash and Cash Equivalents of 116.29M, accounting for 0.18 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6539 go with three margins increasing?

    In the latest report, 麗彤 (6539) did not achieve the “three margins increasing” benchmark, with a gross margin of 71.86%%, operating margin of 0.58%%, and net margin of -2.95%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6539's profit trajectory and future growth potential.